This article is more than 5 years old. Information may no longer be current.
FDA approves Sensus Healthcare’s SRT-100 for keloid treatment
Click Here to Manage Email Alerts
Sensus Healthcare announced today that it has received FDA clearance to treat keloids caused by surgery or injury with its superficial radiotherapy system.
The device, the SRT-100, has been used previously as an alternative to surgery in treating nonmelanoma skin cancer in patients who are not good surgical candidates, according to a press release. It uses the company’s SharpBeam technology, which targets only the lesion and not surrounding and underlying healthy tissue.
Mark S. Nestor
“Painful and potentially disfiguring keloid scars are very difficult to effectively treat by surgery or other means due to recurrence rates as high as 45 to 100%,” Mark S. Nestor, MD, PhD, of the Center for Cosmetic Enhancement in Aventura, Fla., said in the release. “Studies show that the use of adjunctive radiation therapy can dramatically reduce the rate of recurrences.
“It is very fortunate that the FDA has approved .. the first computerized, state of the art in-office SRT device, for the treatment of recurrent keloid scars. Dermatologists now have a safe, effective in-office modality available to offer our keloid patients."